Compare OWLT & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | IMRX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 85 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.6M | 322.8M |
| IPO Year | N/A | 2021 |
| Metric | OWLT | IMRX |
|---|---|---|
| Price | $7.33 | $5.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $20.00 | $17.20 |
| AVG Volume (30 Days) | 175.9K | ★ 687.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.02 | N/A |
| Revenue Next Year | $22.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.75 | $1.10 |
| 52 Week High | $16.94 | $10.08 |
| Indicator | OWLT | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 54.60 |
| Support Level | N/A | $3.93 |
| Resistance Level | $9.63 | $5.36 |
| Average True Range (ATR) | 0.82 | 0.28 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 4.77 | 84.82 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.